Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept
Not yet recruiting
Vista Klinik
Phase 4
2022-11-01
Title: Intravitreal faricimab in diabetic macular edema with limited response to aflibercept
Purpose: The purpose of this investigator initiated study is to identify the effects of
intravitreal faricimab on recurrence-free treatment intervals and morphological features in
diabetic macular edema (DME) in which the Optical coherence tomography (OCT) guided treatment
interval failed to be extended to 6 weeks intervals in a treat and extend regimen using
aflibercept.
Objectives: The primary objective is to evaluate the proportion of patients with an increased
maximum treatment interval with intravitreal faricimab (compared to previous 4-week interval
under aflibercept) in an OCT guided treat and extend regimen at month 6 and 12. (for further
outcome measures see section Objectives)
Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy
Not yet recruiting
University of Colorado, Denver
Phase 4
2024-08-01
In this phase IV, randomized, double-masked, sham-controlled study the investigators hope to
determine the efficacy in peri-operative faricimab (Vabysmo) compared to sham in limiting
complications from pars plana vitrectomy for diabetic vitreous hemorrhage with or without
tractional retinal detachments.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
